A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

Required: AKT1 E17K

solid tumor malignancy harboring AKT1 E17K mutation identified through molecular testing (NGS- or PCR-based)

Excluded: KRAS genomic alteration

Patients known to have KRAS...genomic alterations in their tumor

Excluded: NRAS genomic alteration

Patients known to have NRAS...genomic alterations in their tumor

Excluded: HRAS genomic alteration

Patients known to have HRAS...genomic alterations in their tumor

Excluded: BRAF genomic alteration

Patients known to have BRAF...genomic alterations in their tumor

Must have received: standard-of-care therapy

Progressed on, intolerant to, or declined prior standard-of-care therapy (including targeted therapy, if applicable) appropriate to tumor type and stage

Cannot have received: PI3K inhibitor

Prior treatment with PI3K and/or mTOR inhibitors

Cannot have received: mTOR inhibitor

Prior treatment with PI3K and/or mTOR inhibitors